Comparative Pharmacology
Head-to-head clinical analysis: HYPAQUE M 75 versus IOPAMIDOL 250 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYPAQUE M 75 versus IOPAMIDOL 250 IN PLASTIC CONTAINER.
HYPAQUE-M,75% vs IOPAMIDOL-250 IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated contrast agent that attenuates X-rays, providing radiographic contrast due to high iodine content. It increases the density of vascular structures and tissues, allowing visualization of anatomical structures during imaging procedures.
Iodinated radiographic contrast medium that attenuates X-rays and provides radiopacity in vascular and body cavities. It does not undergo significant pharmacological activity.
1.2-1.5 mL/kg IV as a single dose for CT enhancement; maximum 150 mL per procedure.
250 mg iodine/mL; 1.5 mL/kg (up to 100 mL) IV bolus or infusion for CT imaging.
None Documented
None Documented
Terminal elimination half-life: 1.5-2 hours in normal renal function; prolonged in renal impairment (up to 24-48 hours in anuria).
Terminal elimination half-life: 2 hours (normal renal function); prolonged in renal impairment (up to 30+ hours in severe impairment), dictating contrast dosing intervals
Renal excretion: >95% unchanged via glomerular filtration; biliary/fecal: <5%.
Renal: 95% unchanged via glomerular filtration; biliary/fecal: <5%
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent